Outlook Therapeutics, Inc.'s (NASDAQ:OTLK) Largest Shareholders Are Individual Investors With 31% Ownership, Private Equity Firms Own 31%
Outlook Therapeutics(R) (NASDAQ: OTLK) to Participate Virtual Investor Closing Bell Series
Outlook Therapeutics to Present at the Virtual Investor Pitch Conference
Outlook Therapeutics(R) (NASDAQ:OTLK) Participates in Virtual Investor "What This Means" Segment Hosted by JTC Team
Watch the "What This Means" video hereOutlook CEO, Russ Trenary underscores that LYTENAVA (bevacizumab gamma) has become the first ophthalmic formulation of bevacizumab to receive European Commission
Buy Rating Justified by Outlook Therapeutics' Advancements and Market Prospects
Express News | Outlook Therapeutics Gains Marketing Authorization From European Commission For LYTENAVA To Treat Retina Diseases
Express News | Outlook Therapeutics Inc - Strategic Partnership With Cencora (Formerly Amerisourcebergen) to Support Planned Commercial Launches of Lytenava in EU
Express News | Outlook Therapeutics Inc - Lytenava™ (Bevacizumab Gamma) Receives Ten Years of Market Exclusivity in EU
Express News | Outlook Therapeutics Inc - Advancing Toward Commercial Launch of Lytenava™ (Bevacizumab Gamma) in EU Expected in Calendar Q1 2025
Express News | Outlook Therapeutics® Receives European Commission Marketing Authorization for Lytenava™ (Bevacizumab Gamma) for the Treatment of Wet AMD
Express News | HC Wainwright & Co. Reiterates Buy on Outlook Therapeutics, Maintains $30 Price Target
Buy Rating Affirmed for Outlook Therapeutics on Strong EU Prospects and Solid Financial Position
Q2 2024 Outlook Therapeutics Inc Earnings Call
Earnings Call Summary | Outlook Therapeutics(OTLK.US) Q2 2024 Earnings Conference
The following is a summary of the Outlook Therapeutics, Inc. (OTLK) Q2 2024 Earnings Call Transcript:Financial Performance:Outlook Therapeutics recently secured funding through a private placement, ge
Outlook Therapeutics, Inc. (OTLK) Q2 2024 Earnings Call Transcript
Outlook Therapeutics, Inc. (OTLK) Q2 2024 Earnings Call Transcript
Express News | Outlook Therapeutics Inc - Qtrly Shr Loss $8.01
Outlook Therapeutics | 10-Q: Quarterly report
Express News | Outlook Therapeutics Q2 2024 Adj EPS $(1.55) Misses $(0.85) Estimate
Outlook Therapeutics Had Cash and Cash Equivalents of $47.2 M as of March 31>OTLK
Outlook Therapeutics Had Cash and Cash Equivalents of $47.2 M as of March 31>OTLK
Outlook Therapeutics 2Q Loss/Shr $8.01 >OTLK
Outlook Therapeutics 2Q Loss/Shr $8.01 >OTLK